21546-03-2Relevant articles and documents
Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors
Wang, Chao,Shi, Weiguo,Cai, Lifeng,Lu, Lu,Wang, Qian,Zhang, Tianhong,Li, Jinglai,Zhang, Zhenqing,Wang, Kun,Xu, Liang,Jiang, Xifeng,Jiang, Shibo,Liu, Keliang
, p. 2527 - 2539 (2013/05/21)
The small molecule fusion inhibitors N-(4-carboxy-3-hydroxyphenyl)-2,5- dimethylpyrrole (NB-2) and N-(3-carboxy-4-hydroxyphenyl)-2,5-dimethylpyrrole (A12) target a hydrophobic pocket of HIV-1 gp41 and have moderate anti-HIV-1 activity. In this
Multitarget Compounds Active at a PPAR and Cannabinoid Receptor
-
Page/Page column 55, (2011/04/13)
There is a need for pharmaceutical compounds which have activity at, at least one of a PPAR and a cannabinoid receptor. Thus there are provided such compounds, wherein the compound comprises: a PPAR pharmacophore and a cannabinoid pharmacophore linked together by a moiety comprising a fused bicyclic ring comprising a five membered ring fused with a six membered ring or a six membered ring fused with a six membered ring; wherein the cannabinoid pharmacophore comprises the fused bicyclic ring; and the PPAR pharmacophore comprises a salicylic acid, alkoxybenzylacetic acid or a alkoxyphenylacetic acid functionality; and wherein the PPAR pharmacophore is linked to the bicyclic ring of the cannabinoid pharmacophore through a linker comprising an amine or an amide functional group.